Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 302

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 302
---
 annul the judgment, the judge requested that the parties submit   
 their arguments in writing. The Company submitted its arguments to the German court by way of a brief on April 11, 2025. In May 2025,   
 the German court issued a judgment dismissing the Company’s annulment claim. On July 4, 2025, the Company entered into an agreement     
 with CSL pursuant to which the Company is required to make an immediate payment of $30 and an additional payment of $300, by the        
 Company to CSL subsequent to the closing of Company’s initial public offering, as well as reimburse certain of CSL’s legal              
 expenses and two future payments of $300 and $200 by the Company to CSL upon the achievement of certain global sales milestones.        
 As a result, in the second half of 2024, the Company recorded a provision of $430.                                                      |

The Company’s product has yet
to be approved by FDA and is still in clinical trials and in any event, is not using CSL’s fibrinogen.

<div align='center'>F-46</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

From time to time, the Company
has been and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively,
“Legal Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company
believes will have a material adverse impact on the business or financial statements.

| NOTE 8: | SEGMENT REPORTING |

ASC 280, “Segment Reporting,”
establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise
about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”)
in deciding how to allocate resources and in assessing performance. The Company’s business is comprised of one reportable
segment specializing in development of tissue repair solutions.

The Company’s CODM is its Chief
Executive Officer (“CEO”), who reviews financial information presented on a consolidated basis.

The CODM performs the assessment of
the segment performance by using net income (loss) to monitor budget versus actual results. Segment assets that are reviewed by the CODM
are reported within the Company’s balance sheet